Literature DB >> 30422088

LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI.

Sang Hyun Choi1, Seung Soo Lee1, So Hyun Park1, Kang Mo Kim1, Eunsil Yu1, Yangsoon Park1, Yong Moon Shin1, Moon-Gyu Lee1.   

Abstract

Purpose To (a) evaluate the postsurgical prognostic implication of the Liver Imaging Reporting and Data System (LI-RADS) categories of primary liver cancers and (b) determine the performance of LI-RADS version 2017 in differentiating hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (IHCC) and combined hepatocellular-cholangiocarcinoma (cHCC-CC) at gadoxetic acid-enhanced MRI. Materials and Methods In this retrospective study, 194 patients with cirrhosis and surgically proven single primary liver cancer (53 with cHCC-CC, 44 with IHCC, and 97 with HCC) were evaluated with gadoxetic acid-enhanced MRI between 2009 and 2014. The mean patient age was 57 years (age range, 30-83 years). There were 155 men with a mean age of 56 years (range, 30-81 years) and 39 women with a mean age of 58 years (range, 38-83 years). Two independent readers assigned an LI-RADS category for each nodule. Overall survival (OS), recurrence-free survival (RFS), and their associated factors were evaluated by using the Kaplan-Meier method, log-rank test, and Cox proportional hazard model. Results In the multivariable analysis, the LI-RADS category was an independent factor for OS (hazard ratio, 4.2; P < .001) and RFS (hazard ratio, 2.6; P = .01). The LR-M category showed more correlation with poorer OS and RFS than did the LR-4 or LR-5 category for all primary liver cancers (P < .001 for both), HCCs (P = .01 and P < .001, respectively), and cHCC-CCs (P = .01 and P = .03, respectively). The LR-5 category had a sensitivity of 69% (67 of 97) and a specificity of 87% (84 of 97) in the diagnosis of HCC; most false-positive diagnoses (85%, 11 of 13) were the result of misclassification of cHCC-CCs. Conclusion The Liver Imaging Reporting and Data System (LI-RADS) category was associated with postsurgical prognosis of primary liver cancers, independent of pathologic diagnosis. The LI-RADS enabled the correct classification of most hepatocellular carcinomas (HCCs) and intrahepatic cholangiocarcinomas, whereas differentiation of combined hepatocellular-cholangiocarcinoma from HCC was unreliable. © RSNA, 2018 Online supplemental material is available for this article. See also the editorial by Bashir and Chernyak in this issue.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30422088     DOI: 10.1148/radiol.2018181290

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  29 in total

Review 1.  LI-RADS and transplantation: challenges and controversies.

Authors:  Guilherme M Cunha; Dorathy E Tamayo-Murillo; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2021-01

2.  Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Authors:  Kyoung A Baek; Seung Soo Kim; Hyeong Cheol Shin; Jeong Ah Hwang; Seo-Youn Choi; Woong Hee Lee; Chan Ho Park; Hyoung Nam Lee; Nam Hun Heo
Journal:  Abdom Radiol (NY)       Date:  2020-09

3.  Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study.

Authors:  Alina Makoyeva; Tae Kyoung Kim; Hyun-Jung Jang; Alejandra Medellin; Stephanie R Wilson
Journal:  Radiol Imaging Cancer       Date:  2020-03-27

4.  Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.

Authors:  Xianlun Zou; Yan Luo; John N Morelli; Xuemei Hu; Yaqi Shen; Daoyu Hu
Journal:  Abdom Radiol (NY)       Date:  2021-03-03

Review 5.  Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma.

Authors:  Guilherme Moura Cunha; Victoria Chernyak; Kathryn J Fowler; Claude B Sirlin
Journal:  J Hepatocell Carcinoma       Date:  2021-05-31

Review 6.  Updates on Imaging of Liver Tumors.

Authors:  Arya Haj-Mirzaian; Ana Kadivar; Ihab R Kamel; Atif Zaheer
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

7.  Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.

Authors:  Tyler J Fraum; Roberto Cannella; Daniel R Ludwig; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Eur Radiol       Date:  2019-10-25       Impact factor: 5.315

8.  Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas.

Authors:  Seung-Seob Kim; Sunyoung Lee; Jin-Young Choi; Joon Seok Lim; Mi-Suk Park; Myeong-Jin Kim
Journal:  Abdom Radiol (NY)       Date:  2020-11

9.  A scientometric analysis on hepatocellular carcinoma magnetic resonance imaging research from 2008 to 2017.

Authors:  Da-Wei Yang; Xiao-Pei Wang; Zhen-Chang Wang; Zheng-Han Yang; Xue-Feng Bian
Journal:  Quant Imaging Med Surg       Date:  2019-03

10.  Simultaneous evaluation of perfusion and morphology using GRASP MRI in hepatic fibrosis.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Robert Grimm; Steven Sourbron; Hersh Chandarana; Yohan Son; Susmita Basak; Kyoung-Bun Lee; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  Eur Radiol       Date:  2021-06-12       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.